Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Treatments and outcomes of adult patients with TP53-mutated acute myeloid leukemia (AML) in the real-life –Report of the prospective french observational ALFA-PPP study.

View Full Paper
Ask AI
Bookmark
Share

Authors

TCThomas CluzeauCBClaire BoriesRRRamy Rahmé

Discussion

Loading...

Member takes

Overview

Analysis reveals TP53-mutated AML patients have poor survival outcomes, suggesting treatment approaches may need adjustment.

Key Points

  • Overall survival in TP53-mutated AML patients is notably low, particularly for those receiving less intensive treatment.
  • The study included 1,108 patients, showing logistic regression identified age and blast count as key predictors for TP53 mutations.
  • Observational data from the ALFA-PPP registry provided insights into treatment decisions and outcomes over 24 months.
  • The findings emphasize the need for tailored treatment strategies for patients with adverse cytogenetic risk and TP53 mutations.

Cite This Study

Cluzeau et al. (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e5achttps://doi.org/10.1182/blood-2025-6386
View Full Paper
Ask AI
Bookmark
Share